Adjuvant pembrolizumab versus placebo in resected stage III melanoma

Authors :: Eggermont, Alexander
Blank, Christian
Mandala, Mario
Long, Georgina
Atkinson, Victoria
Dalle, Stéphane
Haydon, Andrew
Lichinitser, Mikhai
Khatta, Adnan
Carlino, Matteo
Sandhu, Shahneen
Larkin, James
Puig, S.
Ascierto, P.
Rutkowski, P.
Schadendorf, D.
Koornstra, R.
Hernandez-Aya, L.
Maio, M.
van den Eertwegh, A.
Grob, J.
Gutzmer, R.
Jamal, R.
Lorigan, Paul C.
Ibrahim, N.
Marreaud, S.
van Akkooi, A.
Suciu, S.
Robert, C.
Eggermont, Alexander
Blank, Christian
Mandala, Mario
Long, Georgina
Atkinson, Victoria
Dalle, Stéphane
Haydon, Andrew
Lichinitser, Mikhai
Khatta, Adnan
Carlino, Matteo
Sandhu, Shahneen
Larkin, James
Puig, S.
Ascierto, P.
Rutkowski, P.
Schadendorf, D.
Koornstra, R.
Hernandez-Aya, L.
Maio, M.
van den Eertwegh, A.
Grob, J.
Gutzmer, R.
Jamal, R.
Lorigan, Paul C.
Ibrahim, N.
Marreaud, S.
van Akkooi, A.
Suciu, S.
Robert, C.
Source :: New England Journal of Medicine
Abstract: Eggermont, A. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V., Dalle, S., ... & Sandhu, S. (2018). Adjuvant Pembrolizumab versus placebo in resected stage III melanoma. New England Journal of Medicine, 378(19), 1789-1801. Available here</a>

Tools